Pre-clinical Trial Results, Expanded Studies, Preliminary Data Release, and Leadership Appointments - Analyst Notes on Alnylam, BioCryst, Puma Biotechnology, Intrexon and NW Bio

NEW YORK, May 30, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Puma Biotechnology, Inc. (NYSE: PBYI), Intrexon Corporation (NYSE: XON) and Northwest Biotherapeutics, Inc. (NASDAQ: NWBO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3120-100free.

--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On May 21, 2014, Alnylam Pharmaceutical, Inc. (Alnylam) announced that pre-clinical results with RNAi therapeutics targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias, including acute intermittent porphyria (AIP) has been published in the Proceedings of the National Academy of Sciences (PNAS). The Company informed that results from the pre-clinical models showed that RNAi therapeutics targeting ALAS-1 can completely block the abnormal production of toxic intermediates of the heme biosynthesis pathway that cause the symptoms and disease pathology of AIP. "We believe ALN-AS1 has the potential to be a transformative therapy for patients with hepatic porphyrias including AIP, an ultra-rare genetic disease with enormous unmet medical need," said Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development of Alnylam. The full analyst notes on Alnylam are available to download free of charge at:

http://www.analystsreview.com/ALNY.pdf/Register

--
BioCryst Pharmaceuticals, Inc. Analyst Notes
On May 27, 2014, BioCryst Pharmaceuticals, Inc. (BioCryst) reported its preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). The Company informed that the trial met the primary efficacy endpoint, several secondary endpoints as well as all other objectives established for the trial. "The efficacy and safety profile of BCX4161 seen in the OPuS-1 trial strongly support its continued development," said Dr. William P. Sheridan, CMO at BioCryst. "We look forward to working with clinical investigators, the HAE community and regulatory authorities in advancing BCX4161 to the next stage and starting the OPuS-2, 12-week trial later this year." The full analyst notes on BioCryst are available to download free of charge at:

http://www.analystsreview.com/BCRX.pdf/Register

--
Puma Biotechnology, Inc. Analyst Notes
On May 14, 2014, Puma Biotechnology, Inc. (Puma Biotechnology) announced the expansion of the first cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). Alan H. Auerbach, CEO and President of Puma Biotechnology said, "We look forward to continuing enrollment into this initially expanded cohort and look forward to expanding additional cohorts from the basket trial, which we anticipate being able to do later this year." The cohorts included in the study are bladder/urinary tract cancer; colorectal cancer; endometrial cancer; gastric/esophageal cancer; ovarian cancer; EGFR mutated and/or amplified primary brain cancer; solid tumors with a HER3 mutation, and all other solid tumors with a HER2 mutation. The full analyst notes on Puma Biotechnology are available to download free of charge at:

http://www.analystsreview.com/PBYI.pdf/Register

--
Intrexon Corporation Analyst Notes
On May 19, 2014, Intrexon Corp. (Intrexon) announced the appointment of Christopher Basta as the Company's Vice President of Investor Relations, with immediate effect. Intrexon's Chairman and CEO, Randal J. Kirk, commented, "We are excited to have Chris join our management team and believe he will make an excellent addition as we continue to grow our business and drive investor interest to create value for the Company and its shareholders." According to Intrexon, Mr. Basta has had over 18 years of financial experience, and most recently served as a consultant for DSP Group directing its investor relations initiatives. The full analyst notes on Intrexon are available to download free of charge at:

http://www.analystsreview.com/XON.pdf/Register

--
Northwest Biotherapeutics, Inc. Analyst Notes
On May 15, 2014, Northwest Biotherapeutics, Inc. (NW Bio) reported preliminary data from an ongoing DCVax-Direct Trial. The Company's specific case study involved a sarcoma patient with large tumor mass and multiple inoperable metastatic tumors in the lung. The patient was given the first 3 DCVax-Direct injections in February 2014. He then received a fourth injection in early April 2014, and then was scanned for results in early May 2014. The patient's MRI showed an extensive necrosis and partial collapse of the injected large tumor mass, and a CT scan showed some early indication of shrinkage of one of the non-injected metastasized tumors. "We are excited to see signs of DCVax-Direct mobilizing the immune system to fight the tumors in these patients with advanced metastatic cancer, even while we are still so early in this ongoing trial and while patients are only part way through their treatments," commented Linda F. Powers, CEO of NW Bio. "We are hopeful that our non-toxic DCVax-Direct may provide a significant new therapeutic option for such patients." The full analyst notes on NW Bio are available to download free of charge at:

http://www.analystsreview.com/NWBO.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review